Cargando…
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Pancreatic ductal adenocarcinoma (PDAC), as the most frequent form of pancreatic malignancy, still is associated with a dismal prognosis. Due to its late detection, most patients are ineligible for surgery, and chemotherapeutic options are limited. Tumor heterogeneity and a characteristic structure...
Autores principales: | Kabacaoglu, Derya, Ciecielski, Katrin J., Ruess, Dietrich A., Algül, Hana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104627/ https://www.ncbi.nlm.nih.gov/pubmed/30158932 http://dx.doi.org/10.3389/fimmu.2018.01878 |
Ejemplares similares
-
NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB
por: Kabacaoglu, Derya, et al.
Publicado: (2019) -
Subtypes of pancreatic stellate cells and distant metastasis of pancreatic ductal adenocarcinoma
por: Fan, Yuhui, et al.
Publicado: (2020) -
An anti-tumor coup: TIM3 ablation activates the immune arsenal
por: Görgülü, Kıvanç, et al.
Publicado: (2021) -
Current and Future Therapies for Pancreatic Ductal Adenocarcinoma
por: Sally, Áine, et al.
Publicado: (2022) -
The Role of Autophagy in Pancreatic Cancer: From Bench to the Dark Bedside
por: Görgülü, Kıvanç, et al.
Publicado: (2020)